Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 21 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

18Total
P 1 (6)
P 2 (11)
P 3 (1)

Trial Status

Completed5
Recruiting5
Withdrawn3
Unknown3
Not Yet Recruiting3
Active Not Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT06949800Phase 2Not Yet Recruiting

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

NCT06563479Phase 3RecruitingPrimary

A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer

NCT04988074Phase 2RecruitingPrimary

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

NCT05639972Phase 1Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05686226Phase 2Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT05973487Phase 1Active Not Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT04979000Completed

HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors

NCT04180215Phase 1CompletedPrimary

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

NCT04369937Phase 2Active Not RecruitingPrimary

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

NCT04900623Phase 2Recruiting

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

NCT03795610Phase 2Completed

IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

NCT03944915Phase 2Completed

De-Escalation Therapy for Human Papillomavirus Negative Disease

NCT03107182Phase 2CompletedPrimary

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

NCT05608369Phase 2WithdrawnPrimary

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC

NCT03423264Phase 2Withdrawn

PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing

NCT06505551Phase 1Not Yet RecruitingPrimary

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

NCT05582590Phase 1Not Yet Recruiting

Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers

NCT05472220Phase 1Withdrawn

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

NCT03895866UnknownPrimary

Persistent Cervical HPV Infection With Clearance and Vaginal Microbiota

NCT03786601UnknownPrimary

Postmenopausal Women With Vaginal Microbiota

Scroll to load more

Research Network

Activity Timeline